Emerging studies suggest Retatru tide , a dual agonist targeting both the gut-brain axis and glucose-dependent insulinotropic polypeptide , may represent a promising advancement for body treatment. Initial clinical investigations have shown impressive decreases in visceral tissue, possibly exceeding current weight-loss treatments. Despite this, mor